Stockscreener 앱 받기
630.25
1.03%
6.71
전일 마감가:
$623.54
열려 있는:
$629.9
하루 거래량:
224.85K
Relative Volume:
0.24
시가총액:
$66.01B
수익:
$14.92B
순이익/손실:
$4.42B
주가수익비율:
15.36
EPS:
41.0422
순현금흐름:
$3.79B
1주 성능:
+1.05%
1개월 성능:
+4.88%
6개월 성능:
-18.39%
1년 성능:
+17.77%
1일 변동 폭
$623.89
$632.85
1주일 범위
$619.70
$638.76
52주 변동 폭
$529.69
$821.11
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
629.60 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
499.49 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
906.30 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.28 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.02 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 재개 | Piper Sandler | Overweight |
| 2026-03-06 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Regeneron Pharma strengthens its position in biotech. Focus on long-term growth and innovation - AD HOC NEWS
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program - BioSpace
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology
Element Squared LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA selects seven companies including Eli Lilly and Regeneron for accelerated manufacturing review pilot - grafa.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Benzinga
Regeneron opens the week with analyst focus, shares on NASDAQ radar - AD HOC NEWS
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? - Insider Monkey
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why - Insider Monkey
How the president of Regeneron pursued his American dream - New York Post
Regeneron clears key moving averages, shares trade below consensus targets - Ad-hoc-news.de
Pictet Asset Management Holding SA Sells 30,616 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The EYLEA injection from Regeneron Pharmaceuticals Inc.high-dose eye therapy pushes into diabetic - Ad-hoc-news.de
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment - simplywall.st
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron myasthenia gravis therapy undergoes US and EU review - MSN
why dominant pharmaceutical firms are paying billion dollar premiums for immunology assets - grafa.com
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biotech's Rapid Response to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance - Investorideas.com
Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX) - The Globe and Mail
Aethlon Medical tracks Ebola outbreak, readies Hemopurifier talks - Stock Titan
Louisiana State Employees Retirement System Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron highlights robust pipeline progress, shares trade in a neutral technical range - Ad-hoc-news.de
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – GETTEX:RGO - TradingView
Price to earnings forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
The EYLEA Injection from Regeneron Pharmahigh-dose eye therapy targets chronic retinal disease - Ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:REGN) - TradingView
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast - The Manila Times
Regeneron schedules July 30 earnings call and webcast - Stock Titan
REGNUS Forecast — Price Target — Prediction for 2027 - TradingView
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $788 - Moomoo
Assenagon Asset Management S.A. Has $160.54 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion - The Business Journals
Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative? - Yahoo Finance
(REGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
BI Asset Management Fondsmaeglerselskab A S Sells 2,968 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc (REGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Regeneron Pharmaceuticals (REGN) Leans On Pipeline Promise As Undervaluation Case Stays In Focus - simplywall.st
Regeneron (REGN) Advances Cemdisiran for Myasthenia Gravis with Regulatory Approvals - GuruFocus
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Regeneron's Applications for gMG Drug Accepted by FDA and EMA - Yahoo Finance
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS) - The Globe and Mail
Regeneron highlights RNAi drug submissions, shares trade in Nasdaq range - AD HOC NEWS
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
2 Underrated Weight Loss Stocks to Buy and Hold - The Motley Fool
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
3.75%
자본화:
|
볼륨(24시간):